Benevich Eric Insider Trades

Insider Trading History

Track insider trading activity for Benevich Eric. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Atyr Pharma
Atyr Pharma ATYR
Director
Holding Value $26.9k 50,000 shares
Last Trade
May 11, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$47.5k 50,000 shares
$0.95
$0.54
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $8.98M 55,639 shares
Last Trade
Feb 13, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$243k 1,961 shares
$124.00
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $633k 3,924 shares
Last Trade
Feb 13, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$243k 1,961 shares
$124.00
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $8.81M 54,581 shares
Last Trade
Feb 13, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$131k 1,058 shares
$124.12
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $336k 2,083 shares
Last Trade
Feb 13, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$258k 2,083 shares
$124.00
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $8.97M 55,540 shares
Last Trade
Feb 13, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$140k 1,124 shares
$124.12
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $5.86M 36,287 shares
Last Trade
Feb 13, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.5M 36,287 shares
$124.12
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $9.15M 56,664 shares
Last Trade
Feb 13, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$258k 2,083 shares
$124.00
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $1.03M 6,365 shares
Last Trade
Feb 13, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$789k 6,365 shares
$124.00
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $10.2M 63,190 shares
Last Trade
Feb 13, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.11M 8,963 shares
$124.12
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $11.6M 72,153 shares
Last Trade
Feb 13, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.06M 16,613 shares
$124.00
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $971k 6,017 shares
Last Trade
Feb 12, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$247k 2,005 shares
$123.10
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $8.67M 53,678 shares
Last Trade
Feb 12, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$133k 1,082 shares
$123.10
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $8.84M 54,760 shares
Last Trade
Feb 12, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$247k 2,005 shares
$123.10
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $8.52M 52,755 shares
Last Trade
Jan 31, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$176k 1,292 shares
$136.06
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $0 0 shares
Last Trade
Jan 31, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$312k 2,294 shares
$136.06
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $8.73M 54,047 shares
Last Trade
Jan 31, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$312k 2,294 shares
$136.06
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $9.32M 57,723 shares
Last Trade
Nov 28, 2025 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$1.95M 12,830 shares
$152.16
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $0 0 shares
Last Trade
Nov 28, 2025 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$1.95M 12,830 shares
$152.16
$161.44
Neurocrine Biosciences
Neurocrine Biosciences NBIX
Chief Commercial Officer
Holding Value $8.21M 50,863 shares
Last Trade
Nov 28, 2025 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$908k 5,970 shares
$152.16
$161.44

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up